Summary: In male patients with diabetes mellitus-induced erectile dysfunction (DMED), combination therapy with moxibustion plus low-dose tadalafil (5 mg daily)…
Browsing: Type 2 Diabetes
Landmark trials and recent evidence on type 2 diabetes management, glucose-lowering therapy, and outcomes.
Clinical Context Curcumin, the principal bioactive compound in turmeric (Curcuma longa), has been studied extensively for anti-inflammatory, antioxidant, and metabolic…
A prespecified DARE-19 analysis found dapagliflozin was safe and well tolerated in hospitalised COVID-19 patients regardless of type 2 diabetes status, with no demonstrated efficacy benefit. PICO summary and expert commentary.
Summary: In type 2 diabetic patients undergoing single simple dental extractions, amoxicillin did not significantly reduce the risk of alveolar…
A double-blind RCT finds empagliflozin gives broader cardiometabolic benefit than sitagliptin or metformin as add-on therapy in type 2 diabetes. PICO summary and commentary.
An RCT finds a periodontal health programme improves oral hygiene and knowledge in older diabetic patients, but not oral-health quality of life. PICO summary and commentary.
A machine-learning analysis finds lower baseline periodontal severity and HbA1c predict better response to gum therapy in diabetes (random forest AUC 0.83). PICO summary and commentary.
A post-hoc analysis of 307 ACCORD-BP participants with type 2 diabetes and prior stroke links intensive systolic blood pressure control to fewer cardiovascular events. PICO summary and expert commentary.
A 24-week trial finds high-phenolic olive oil reduces insulin resistance in type 2 diabetes, but without changing lipids or blood pressure. PICO summary and commentary.
A randomized open-label pilot trial tested whether slower, flexible semaglutide titration reduces gastrointestinal dropout in type 2 diabetes versus the label regimen. PICO summary and expert commentary.